{"organizations": [], "uuid": "0aa4398336f5db2844eb4a39d6d51af16e7fb7d4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-minerva-neurosciences-screens-firs/brief-minerva-neurosciences-screens-first-patient-in-phase-2b-trial-ofmin-117-to-treat-major-depressive-disorder-idUSASC09V9F", "country": "US", "domain_rank": 408, "title": "BRIEF-Minerva Neurosciences Screens First Patient In Phase 2B Trial Of Min 117 To Treat Major Depressive Disorder", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-09T16:09:00.000+03:00", "replies_count": 0, "uuid": "0aa4398336f5db2844eb4a39d6d51af16e7fb7d4"}, "author": "", "url": "https://www.reuters.com/article/brief-minerva-neurosciences-screens-firs/brief-minerva-neurosciences-screens-first-patient-in-phase-2b-trial-ofmin-117-to-treat-major-depressive-disorder-idUSASC09V9F", "ord_in_thread": 0, "title": "BRIEF-Minerva Neurosciences Screens First Patient In Phase 2B Trial Of Min 117 To Treat Major Depressive Disorder", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-minerva neurosciences screens", "sentiment": "negative"}, {"name": "treat major depressive disorder reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "minerva neurosciences inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 9, 2018 / 1:10 PM / Updated 6 minutes ago BRIEF-Minerva Neurosciences Screens First Patient In Phase 2B Trial Of Min 117 To Treat Major Depressive Disorder Reuters Staff 1 Min Read \nApril 9 (Reuters) - Minerva Neurosciences Inc: \n* MINERVA NEUROSCIENCES SCREENS FIRST PATIENT IN PHASE 2B TRIAL OF MIN 117 TO TREAT MAJOR DEPRESSIVE DISORDER \n* 117 ARE EXPECTED IN FIRST HALF OF 2019 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)", "external_links": [], "published": "2018-04-09T16:09:00.000+03:00", "crawled": "2018-04-09T16:22:06.011+03:00", "highlightTitle": ""}